Delivery Order SPE2DB24D6041-SPE2DB25FKCBK

Award Date 5/15/25
Potential Completion Date 5/16/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,248.58 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of May 1, 2025 and is not set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $47,865.60 firm-fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,554.20 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of May 28, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,755.67 Firm Fixed Price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 21, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,078.11 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S and has a completion date of June 28, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,680.82 fixed-price delivery order contract is for the delivery of ELIQUIS 5 MG TABLET 60S, with a period of performance through January 2, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $13,072.56 Firm Fixed Price Delivery Order contract is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of March 12, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,004.29 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a cardiovascular medication. The contract has an ultimate completion date of February 28, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,211.30 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a prescription medication. The contract has a performance period extending through May 15, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger $999,999,999.00...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,176.85 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, a medical product, with a completion date of January 30, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
  • SPE2DB24D6041
    Indefinite Delivery Contract
  • SPE2DB24D6041-SPE2DB25FKCBK
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,427.94 firm fixed-price delivery order is for the supply of ELIQUIS 5 MG TABLET 60S, with a completion date of May 16, 2025.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The contract award does not indicate a set-aside designation, suggesting open competition.

Generated 8/14/25, 9:49 AM